Hidradenitis suppurativa is one of the most distressing conditions in dermatology with a remarkable negative effect on patients’ quality of life.1 Despite recent advances, there is still a great unmet need for effective long-term treatments for moderate and severe forms.1-3 Increased levels of cytokines associated with innate immunity, such as interleukin [IL]-1β, have been found in hidradenitis suppurativa skin samples.4 Canakinumab is a human IgGκ monoclonal antibody targeting IL-1β, and it modulates multiple proinflammatory and anti-inflammatory mediators. Therefore, canakinumab might represent an alternative treatment for hidradenitis suppurativa.2,3 We describe the efficacy of canakinumab in 2 patients with severe hidradenitis suppurativa (Hurley clinical stage III) who had poor response to standard treatment regimens.
Houriet C, Seyed Jafari SM, Thomi R, et al. Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases. JAMA Dermatol. 2017;153(11):1195–1197. doi:10.1001/jamadermatol.2017.2392
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: